A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II

Inclusion Criteria: * Male or female adult subjects 18 years of age and older. * Confirmed diagnosis of HAE type I or II at anytime in the medical history * At least 3 documented HAE attacks in the past 93 days, as supported by medical history. * Access to and ability to use conventional attack treatment for attacks of HAE * Adequate organ functions * Females of childbearing potential must agree to use highly effective birth control from the Screening visit until the end of the trial follow-up procedures. * Females of non-childbearing potential, defined as surgically sterile (status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or post-menopausal for at least 12 months, do not require contraception during the study * Males with female partners of childbearing potential must agree to be abstinent or else use a highly effective method of birth control as defined in inclusion 6 from the Screening visit until the end of the trial follow-up procedures * Provide signed informed consent and are willing and capable of complying with study requirements and procedures Exclusion Criteria: * Any concomitant diagnosis of another form of chronic angioedema, such as acquired C1 inhibitor (C1-INH) deficiency, HAE with normal C1-INH (also known as HAE type III), idiopathic angioedema, or angioedema associated with urticaria * Current use of C1INH, androgens, or tranexamic acid for HAE prophylaxis * Use of angiotensin-converting enzyme (ACE) inhibitors or any estro…